Objective: Antiretroviral therapy (ART) has been implicated in bone loss in HIV. The role of inflammation and vitamin D is unclear and better investigated in ART-naive individuals.
Introduction
People are living with HIV infection longer than ever before due to advances in antiretroviral therapy (ART) over the past two decades [1] . Bone health has become an increasingly important aspect of the long-term care of HIV-infected individuals because of the higher prevalence of osteoporosis [2] and demonstrated higher risk of fractures including fragility fractures compared with the general population [3] . Understanding the pathogenesis of bone loss in HIV is imperative for developing targeted approaches to fracture prevention in this high-risk group.
Multiple factors likely contribute to the pathogenesis of low bone mineral density (BMD) and bone loss in HIV. Some traditional osteoporosis risk factors may disproportionately affect HIV-infected individuals including low body weight, hypogonadism, and smoking, and these have been shown to be important causes of low BMD in HIV [4, 5] . Direct effects of ART, specifically tenofovir and protease inhibitors, have been implicated as well [6] [7] [8] [9] . However, regardless of the regimen selected, ART initiation has been shown to result in a 2-6% loss of BMD after 48-96 weeks [10, 11] with subsequent stabilization [12] . Further, the degree of bone loss after ART initiation has been linked with CD4 þ T-cell count, suggesting a role for degree of pre-ART immunodeficiency [13] . Most recently, the effect of HIV itself and consequent chronic inflammation has been suggested as a contributor [14] . Low BMD is prevalent in ART-naive, HIV-infected individuals [8, 11, 15] . At the time of enrollment into A5224s, a substudy of AIDS Clinical Trials Group Study A5202, 39% of HIV-infected, ARTnaive participants were osteopenic at the hip or spine [11] . It is notable that 85% of these participants were men and the median age was 38 years, which, if HIV-uninfected, should have been considered at low risk for bone disease. This suggests that HIV infection and/or heightened inflammation may be impacting BMD in HIV, independently of the effect of ART. Higher markers of inflammation have been linked with risk of fracture in HIV-uninfected adults as well [16] .
To date, studies evaluating changes in BMD over time in HIV have included participants initiating ART [10, 13] or ART-experienced [4, 5, [17] [18] [19] [20] [21] [22] . The aim of this study was to evaluate the change in BMD without the confounding effect of ART with a well matched HIV-uninfected comparator group and report the association with markers of systemic inflammation. In addition, given the very high prevalence of vitamin D deficiency in HIV [23] , we aimed to assess the effect of vitamin D status on skeletal health. The hypothesis of this study was that over 48 weeks, HIV-infected, ART-naive adults would have greater loss of BMD at the hip and spine measured by dual-energy X-ray absorptiometry (DXA) compared to HIV-uninfected controls matched by age, sex, and race. Secondary hypotheses were that bone loss in the HIVinfected group would be associated with higher markers of systemic inflammation and lower vitamin D levels.
Methods

Study design
A 48-week, prospective, matched cohort study was performed on HIV-infected, ART-naive adults and HIVuninfected controls matched by age, sex, and race to determine the effect of HIV, systemic inflammation, and vitamin D concentration, assessed by plasma 25-hydroxyvitamin D [25(OH)D], on BMD over time. HIVinfected individuals at least 18 years old who were naive to ART and unlikely to require ART for at least 48 weeks based on ART treatment guidelines at the time (ART initiation recommended at CD4 þ cell count 350 cells/ml) [24] were eligible for inclusion in the HIV-infected group. Individuals at least 18 years old without known HIV infection or any medical condition requiring the use of prescription medications were eligible for the control group. Exclusion criteria for both groups included: diabetes mellitus defined as fasting blood glucose level above 126 mg/dl, any active infectious or inflammatory condition, pregnancy or breastfeeding. HIV-infected individuals were recruited from the John T. Carey Special Immunology Unit at University Hospitals Case Medical Center (UHCMC) in Cleveland, Ohio. Control participants were UHCMC employees, friends and family members of the HIV-infected participants, and community members responding to an invitation to participate received through the mail. Controls were matched by age within 3 years, sex, and race to a previously enrolled HIV-infected participant. All participants signed a written informed consent prior to enrollment into this study. Both the study consent and protocol were approved by the UHCMC Institutional Review Board prior to the enrollment of any participants.
The primary outcomes in this study were changes in hip and spine BMD measured by DXA over 48 weeks. Secondary outcomes of interest included: changes in plasma 25(OH)D and markers of inflammation over 48 weeks; proportion of participants with bone loss over 48 weeks; and proportion of participants with progression from normal bone to osteopenia or osteopenia to osteoporosis over 48 weeks. The 48-week time point was selected for follow-up in this study for two reasons. First, the aim of this study was to evaluate ART-naive HIV-infected individuals who remained ART-naive through study follow-up to assess the effect of HIV on BMD progression without the confounding effect of ART. At the time this study began, average time to ART initiation was approximately 2 years in our clinic. Therefore, choosing 48-week follow-up would permit two DXAs prior to ART initiation on most enrolled participants. Second, in ART initiation studies, 48 weeks has been sufficient to detect a significant change in BMD [10] .
Bone mineral density measurement Dual-energy X-ray absorptiometry of the spine and left hip was performed at study entry and week 48. All DXA scans were performed at a single site (UHCMC) on all study participants using a Hologic QDR-4500A (Hologic Inc, Bedford, Massachusetts, USA). The scans were assessed with a dedicated densitometer and a technologist who was blinded to the HIV status of the study participants. Osteopenia was defined as a T-score of À1 or less and greater than -2.5 at any of the sites measured. Osteoporosis was defined as a T-score of -2.5 or less at any of the sites measured.
Inflammatory biomarkers and vitamin D Participants had blood drawn after a 12-h fast at entry and week 48. Plasma was stored at À808C and never thawed until analysis. Stored samples were batched and tested for inflammatory markers including high-sensitivity C-reactive protein (hsCRP), interleukin-6 (IL-6), soluble tumor necrosis factor (TNF)-a receptors (sTNFR-l and sTNFR-II), adhesion molecules/endothelial activation markers including soluble vascular cell adhesion molecule-1 (sVCAM-1) and soluble intercellular adhesion molecule-1 (sICAM-1) and 25(OH)D. IL-6, sTNFR-I and II, sVCAM-1 and sICAM-1 were determined by quantitative sandwich ELISAs (R&D Systems, Minneapolis, Minnesota, USA). Inter-assay variability ranged from 2.02 to 15.36%, 3.66 to 5.77%, 2.13 to 3.79%, 4.76 to 8.77% and 3.43 to 7.37%, respectively. hsCRP was determined by particle-enhanced immunonephelometric assays on a BNII nephelometer (Siemens, Indianapolis, Indiana, USA). Inter-assay variability ranged from 3.01 to 6.46%. All inflammatory marker assays were performed at the Laboratory for Clinical Biochemistry Research University of Vermont.
Plasma 25(OH)D was determined by chemiluminescent technique with the iSYS fully automated system (IDS, Ltd, Fountain Hills, Arizona, USA). All samples were analyzed in the same co-investigator's laboratory (Vermont, USA) at Emory University by experienced personnel. This laboratory participates in the National Institutes of Health Vitamin D Quality Control Project as well as the Vitamin D External Quality Assessment Scheme (DEQAS, site 606). Intra and inter-assay variability was less than 8 and 10%, respectively, and this assay correlates well with established methods to determine 25(OH)D (R 2 ¼ 0.89 vs. radioimmunoassay). In this study, vitamin D insufficiency was defined as plasma 25(OH)D below 30 ng/ml and at least 20 ng/ml, and vitamin D deficiency plasma 25(OH)D below 20 ng/ml [25] .
CD4 þ T-cell counts and HIV-1 RNA levels were measured as part of clinical care concurrently with the other measures.
Data analysis
Demographics are presented overall and by group at baseline. Median and interquartile range (IQR) are reported for continuous variables, and frequency and percentage for categorical variables. All baseline demographics as well as endpoints were compared between groups using unpaired t-tests or Wilcoxon rank-sum tests as distributionally appropriate for continuous variables and by chi-square tests, Fisher's exact tests, or Pearson exact chi-square tests as appropriate for categorical variables. Within-group changes were tested using paired t-tests or Wilcoxon signed-rank tests as distributionally appropriate. Analysis of co-variance (ANCOVA) was used to adjust baseline BMD at each site for age, sex, race, BMI, and smoking status. Adjusted means were compared between groups using unpaired t-tests. Univariable followed by multivariable linear regression was used to determine associations between baseline BMD at each site and variables of interest including HIV status, demographics, inflammatory markers, and 25(OH)D levels. Stepwise selection was used to generate final models considering all variables with P 0.25 or less in univariable analyses.
Bone loss was defined as a negative change in BMD over 48 weeks. Proportion of participants with bone loss at each site separately, and at any site (composite outcome), as well as proportion of participants with progression from normal bone to osteopenia or osteopenia to osteoporosis at any site (composite outcome), were compared between groups using chi-square tests or Fisher's exact tests as appropriate. With bone loss at each site, bone loss at any site, and progression from normal bone to osteopenia or osteopenia to osteoporosis, as the dependent variables, logistic regression was used to adjust for age, sex, race, BMI, smoking, and hepatitis C status. Next, an exploratory analysis was performed using logistic regression to determine if baseline inflammation or 25(OH)D level was in the causal pathway of bone loss at the trochanter site. A model was created with bone loss at the trochanter site as the dependent variable and HIV status as the only independent variable. To this model each inflammatory marker and 25(OH)D level at baseline were added in turn to ascertain the effect of this added variable on the HIV status odds ratio (OR). A change in the HIV status OR of above 10% was considered suggestive that this factor was in the causal pathway of why HIV was associated with bone loss at this site. Lastly, in the HIV-infected group, logistic regression was used to explore predictors of progression from normal BMD to osteopenia or osteopenia to osteoporosis. For this model, stepwise selection was used considering the following variables of interest: IL-6, hsCRP, sTNFR-I, sTNFR-II, sVCAM-1, sICAM-1, 25(OH)D, age, sex, race, BMI, smoking, baseline CD4 þ T-cell count, HIV-1 RNA level, and known duration of HIV infection.
All statistical tests were two-sided and considered significant with P less than 0.05. Analyses were performed using SAS v. 9.2 (SAS Institute, Cary, North Carolina, USA).
Results
From 13 July 2010 to 22 August 2012, 88 participants were enrolled including 47 HIV-infected individuals and 41 controls. Of the 88 participants enrolled, 11 (12.5%) did not complete the study (7/47 (8.5%) in the HIVinfected group and 4/41 (9%) in the control group). Two participants moved, one was incarcerated and the rest were lost to follow-up. As such, for the longitudinal analysis of BMD, 40 HIV-infected participants and 37 controls were included. Table 1 shows baseline demographic factors by group. The groups were similar with regard to all baseline factors except there were more current smokers (72 vs. 15%; P < 0.0001) and participants with hepatitis C (19 vs. 2%; P ¼ 0.017) in the HIV-infected group. Overall, 69% were men and 68% were African American. Median (IQR) age was 38 Total hip BMD (g/cm 2 ) À0.005 (À0.026-0.008) a 0 (À0.024-0.012) 0.23 Femoral neck BMD (g/cm 2 ) À0.003 (À0.03-0.013) À0.006 (À0.024-0.011) 0.87 Trochanter BMD (g/cm 2 ) À0.013 (À0.03-0.003) a 0.001 (À0.023-0.014) 0.09 Spine BMD (g/cm 2 ) À0.003 (À0.024-0.027) 0 (À0.015-0.02) 0.89 ART, antiretroviral therapy; BMD, bone mineral density. All values are reported as median (interquartile range). a P < 0.05 within group. heightened inflammation is in the causal pathway and is a possible explanation for why HIV status was associated with this outcome.
In case of HIV-infected participants, 20.5% progressed from normal bone to osteopenia or from osteopenia to osteoporosis vs. 5.6% of controls (P ¼ 0.089). In the HIV-infected group, higher baseline IL-6 (OR 1.1, 95% CI 1-1.2, P ¼ 0.036) and Caucasian race (OR 17.4, 95% CI 2.1-142, P ¼ 0.008) were independently associated with this outcome in multivariable modeling. Other inflammatory markers, 25(OH)D level and HIV-related factors including baseline CD4 þ T-cell count were not independently associated with this outcome.
Discussion
In this study, we have comprehensively assessed change in BMD and the association with inflammation and vitamin D status in HIV-infected adults naive to ARTwith an age, sex, and race-matched healthy control group for comparison. Similar to previous studies [8, 11, 15] , the prevalence of low BMD in the ART-naive HIV-infected group at baseline was high (36%); however, it was similar to what was seen in the matched controls (32%). Low baseline BMD in this study was associated with traditional osteoporosis risk factors including older age, low BMI, and female sex. Over 48 weeks, BMD decreased significantly at both the total hip and trochanter sites in the HIV-infected group, but again the changes in BMD were not statistically different than matched healthy controls. However, after adjustment for traditional osteoporosis risk factors, the ART-naive HIV-infected adults were more likely to have bone loss at the trochanter site than controls, and this risk appeared to be associated with heightened inflammation. Also, progression from normal bone to osteopenia or from osteopenia to osteoporosis was independently associated with higher baseline IL-6 levels in the HIV-infected group. Lastly, although vitamin D deficiency was common in both groups in this study, vitamin D status was not associated with change in BMD.
It has been suggested that the process of bone resorption and bone formation (or bone remodeling), which is normally a tightly regulated balance, is uncoupled in HIV [26] . HIV viral proteins have been shown to directly stimulate osteoclast activity [27] and suppress osteoblast activity [28] . Further, TNF-a and IL-6, inflammatory cytokines known to be elevated in both ART-treated and untreated-HIV-infected individuals compared to uninfected controls [29, 30] , both promote osteoclast formation [31] [32] [33] . In this study, given the suggestion that systemic inflammation contributes to the risk of bone loss at the trochanter site, perhaps with longer follow-up, greater differences would be seen with regard to change in Low vitamin D has been linked to low BMD [34, 35] and replacement of vitamin D has been shown to improve BMD [36] outside HIV; however, we did not find a link in our study. In HIV, our study is congruent with the study by Sherwood et al. [37] which showed that vitamin D deficiency [25(OH)D < 30 ng/dl] was not associated with low BMD in military beneficiaries with HIV, and with a study by El-Maouche et al. [38] which showed that vitamin D deficiency [25(OH)D < 15 ng/dl] was not associated with low BMD in hepatitis C virus (HCV)/ HIV co-infected adults. Potential explanations include the fact that African American race, which has been shown to effect the relationship between 25(OH)D and BMD [39, 40] , was the most predominant race in this study. Also, it was recently recognized that in the general population, measurements of free 25(OH)D, and not just total 25(OH)D, are better correlated with BMD [41] . Lastly, most of the participants in this study -HIVinfected and controls -were vitamin D-deficient, so we were unable to compare change in BMD with a vitamin D-sufficient group. Ongoing vitamin D supplementation trials will be able to establish a causal link in the relationship between vitamin D status and BMD in HIV.
Despite the uniqueness of our study and our population, we should point out some limitations. The study was powered to detect large differences between groups in change in BMD over 48 weeks, which were not seen. Assuming a SD of changes from baseline to week 48 within an arm of 0.03, a sample size of 77 participants had 80% power (two-sided t-test with an alpha of 0.05) to detect an absolute difference in mean change between arms of 0.0194 g/cm 2 . In this study, the actual difference in BMD between groups at the trochanter site was 0.0095 g/cm 2 . Further, although studies evaluating changes in BMD after ART initiation have shown significant differences after 48 weeks, the 48-week duration remains relatively short for the evaluation of changes in BMD. Further, because we have only evaluated participants at two time points, it is not clear that the effect of HIVon change in BMD at the trochanter site is constant over time, that is a linear relationship, or that the risk of bone loss at the trochanter site seen in this study will be the similar over longer periods of follow-up. Next, we did not adjust for multiple comparisons given the exploratory nature of the inflammation analyses. Lastly, the menopausal status of the women in this study was not captured; however, the control group was matched by both age and sex.
In conclusion, HIV-infected, ART-naive adults, but not controls, had BMD loss at the total hip and trochanter sites over this 48-week, matched, prospective cohort study, although changes in BMD did not reach statistical significance between the groups. The HIV-infected individuals were more likely to have bone loss at the trochanter site and this may be related to heightened inflammation. Further, higher baseline IL-6 was associated with progression to osteopenia or osteoporosis in the HIV-infected group. 25(OH)D concentration at baseline was not associated with baseline or change in BMD in this study. Therapeutics targeting inflammation may benefit bone health in HIV-infected adults naive to ART and further study in this area is needed.
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